

AMENDMENTS TO THE CLAIMS:

Please amend claims 18, 26, 30 and 81 as follows. This listing of claims replaces all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

1-17. (Canceled)

18. (Currently Amended) A method for determining the amount of free gastrin-17 (G17) or gastrin-34 (G34) in a biological fluid sample, comprising the steps of:

- (a) obtaining a biological fluid sample comprising a gastrin hormone from a patient;
- (b) providing an immobilized antibody selected from the group consisting of an immobilized antibody that selectively binds an N-terminal epitope of G17 and an immobilized antibody that selectively binds an N-terminal epitope of G34;
- (c) incubating the sample to allow binding of G17 or G34 in the sample to said antibody to produce an immobilized complex of said antibody bound to the G17 or G34;
- (d) washing the immobilized complex to remove unbound ~~antibody~~ G17 or G34, and reacting the complex with a detectable marker-conjugated monoclonal antibody that selectively binds a C-terminal epitope of G17 or G34, to form a detectable marker-conjugated antibody complex;
- (e) washing the immobilized detectable marker-conjugated antibody complex, and incubating with a development reagent; and
- (f) measuring the developed reagent to determine the amount of free G17 or free G34 in the biological fluid sample;

wherein the monoclonal antibody that selectively binds a C-terminal epitope of G17 or G34 is the monoclonal antibody produced by the hybridoma 458-1 (ATCC accession no. PTA-5896).

19-25. (Canceled)

26. (Currently Amended) A method for determining the amount of free G34 in a biological fluid sample, comprising the steps of:

- (a) obtaining a biological fluid sample comprising the gastrin hormone G34;

(b) providing an immobilized monoclonal antibody that selectively binds an N-terminal epitope of G34;

(c) incubating the sample to allow binding of the G34 in the sample to said antibody to produce an immobilized complex of said antibody bound to the G34;

(d) washing the immobilized complex to remove unbound ~~antibody~~ G34, and reacting the complex with a detectable marker-conjugated antibody that selectively binds a C-terminal epitope of G34, to form a detectable marker-conjugated antibody complex;

(e) washing the immobilized detectable marker-conjugated antibody complex, and incubating with a development reagent; and

(f) measuring the developed reagent to determine the amount of free G34 in the biological fluid sample;

wherein the immobilized monoclonal antibody is the monoclonal antibody produced by the hybridoma 401-2 (ATCC accession no. PTA-5893).

27-29. (Canceled)

30. (Currently Amended) A method for determining the amount of free Glycine-extended G17 or Glycine- extended G34 in a biological fluid sample, comprising the steps of:

(a) obtaining a biological fluid sample comprising a gastrin hormone from a patient;

(b) providing an immobilized antibody selected from the group consisting of an immobilized antibody that selectively binds an N-terminal epitope of Glycine-extended G17 and an immobilized antibody that selectively binds an N-terminal epitope of Glycine-extended G34;

(c) incubating the sample to allow binding of Glycine-extended G17 or Glycine-extended G34 in the sample to said antibody to produce an immobilized complex of said antibody bound to the Glycine-extended G17 or Glycine-extended G34;

(d) washing the immobilized complex to remove unbound ~~antibody~~ Glycine-extended G17 or Glycine-extended G34, and reacting the complex with a detectable marker-conjugated monoclonal antibody that selectively binds a C-terminal epitope of Glycine-extended G17 or Glycine-extended G34, to form a detectable marker-conjugated antibody complex;

(e) washing the immobilized detectable marker-conjugated antibody complex, and incubating with a development reagent; and

(f) measuring the developed reagent to determine the amount of free Glycine-extended G17 or Glycine-extended G34 in the biological fluid sample;

wherein the monoclonal antibody is the monoclonal antibody produced by the hybridoma 445-1 (ATCC accession no. PTA-5894) or the monoclonal antibody produced by the hybridoma 445-2 (ATCC accession no. PTA-5895).

31-80. (Canceled)

81. (Currently Amended) A method for determining the amount of free Glycine-extended G34 in a biological fluid sample, comprising the steps of:

(a) obtaining a biological fluid sample comprising the gastrin hormone Glycine-extended G34;

(b) providing an immobilized monoclonal antibody that selectively binds an N-terminal epitope of Glycine-extended G34;

(c) incubating the sample to allow binding of the Glycine-extended G34 in the sample to said antibody to produce an immobilized complex of said antibody bound to the Glycine-extended G34;

(d) washing the immobilized complex to remove unbound ~~antibody~~ Glycine-extended G34, and reacting the complex with a detectable marker-conjugated antibody that selectively binds a C-terminal epitope of Glycine-extended G34, to form a detectable marker-conjugated antibody complex;

(e) washing the immobilized detectable marker-conjugated antibody complex, and incubating with a development reagent; and

(f) measuring the developed reagent to determine the amount of free Glycine-extended G34 in the biological fluid sample;

wherein the immobilized monoclonal antibody is the monoclonal antibody produced by the hybridoma 401-2 (ATCC accession no. PTA-5893).

82-89. (Canceled)

90. (Previously Presented) The method of claim 18, wherein the immobilized antibody of step (b) is a monoclonal antibody.

91. (Previously Presented) The method of claim 90, wherein the immobilized monoclonal antibody selectively binds an N-terminal epitope of G17.

92. (Previously Presented) The method of claim 91, wherein the immobilized monoclonal antibody that selectively binds an N-terminal epitope of G17 is the antibody produced by the hybridoma 400-1 (ATCC accession no. PTA-5889), hybridoma 400-2 (ATCC accession no. PTA-5890), hybridoma 400-3 (ATCC accession no. PTA-5891) or the monoclonal antibody produced by the hybridoma 400-4 (ATCC accession no. PTA-5892).

93. (Previously Presented) The method of claim 90, wherein the monoclonal antibody selectively binds an N-terminal epitope of G34.

94. (Previously Presented) The method of claim 93, wherein the monoclonal antibody that selectively binds an N-terminal epitope of G34 is the monoclonal antibody produced by the hybridoma 401-2 (ATCC accession no. PTA-5893).

95 (Previously Presented) The method of claim 26, wherein the antibody that selectively binds a C-terminal epitope of G34 is a monoclonal antibody.

96 (Previously Presented) The method of claim 95, wherein the monoclonal antibody that selectively binds a C-terminal epitope of G34 is the monoclonal antibody produced by the hybridoma 458-1 (ATCC accession no. PTA-5896).

97 (Previously Presented) The method of claim 30, wherein the immobilized antibody of step (b) is a monoclonal antibody.

98 (Previously Presented) The method of claim 97, wherein the immobilized monoclonal antibody is a monoclonal antibody that selectively binds an N-terminal epitope of Glycine-extended G17.

99 (Previously Presented) The method of claim 98, wherein the immobilized monoclonal antibody that selectively binds an N-terminal epitope of Glycine-extended G17 is the antibody produced by the hybridoma 400-1 (ATCC accession no. PTA-5889), hybridoma 400-2 (ATCC accession no. PTA-5890), hybridoma 400-3 (ATCC accession no. PTA-5891) or the monoclonal antibody produced by the hybridoma 400-4 (ATCC accession no. PTA-5892).

100. (Previously Presented) The method of claim 97, wherein the immobilized monoclonal antibody is a monoclonal antibody that selectively binds an N-terminal epitope of Glycine-extended G34.

101 (Previously Presented) The method of claim 100, wherein the immobilized monoclonal antibody that selectively binds an N-terminal epitope of Glycine-extended G34 is the monoclonal antibody produced by the hybridoma 401-2 (ATCC accession no. PTA-5893).

102. (Previously Presented) The method of claim 81, wherein the antibody that selectively binds a C-terminal epitope of Glycine-extended G34 is a monoclonal antibody.

103. (Previously Presented) The method of claim 102, wherein the monoclonal antibody that selectively binds a C-terminal epitope of Glycine-extended G34 is the monoclonal antibody produced by the hybridoma 445-1 (ATCC accession no. PTA-5894) or the monoclonal antibody produced by the hybridoma 445-2 (ATCC accession no. PTA-5895).